An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time oncology review, expediting access to this potential treatment. The FDA has ...

ANI India will face over USD 14.6 bn in additional duties, if US imposes 20 per cent tariff: BCG Report The ASEAN region, alongside India, stands out as a major beneficiary of the ongoing geopolitical ...

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer. Sasanlimab (PF-06801591) in combination with Bacillus Calmette-Guérin (BCG) led ...